The Negative Effects of Drugs

Drugs are very important in the treatment of the various health problems that occur within the human population. Although drugs are important, some tend to have some very serious side effects on the patients who use them. In this paper, we shall discuss two drugs which have a high risk of giving patients some serious side effects.

There is a high risk for Multiple Sclerosis patients who take the drug Ampyra. The majority of these seizures occur within days of starting the dosage especially among those patients who had no prior history of seizures and it is advised that patients who miss a dose should not take extra doses because doing so will increase the seizure risk. Patients should stop taking the drug right away if they develop any problems and should immediately contact their doctors for advice about what to do next. The healthcare professional should order his patients’ blood tests periodically to monitor the kidney functions of their Multiple Sclerosis patients in order to reduce the chances of a seizure due to the use of Ampyra.

Healthcare professionals are supposed to regulate the dosage of the antibacterial drug cefepime in patients with kidney impairment because there have been some cases of a specific type of seizure called non - conclusive status epilepticus associated with the use of cefepime especially among patients with kidney problems who did not receive appropriate dosage adjustments of the drug. To minimize the risk of seizures, healthcare professionals should adjust the dosage of cepefime in patients with creatinine clearance less than or equal to 60mL/min and if seizures associated with cefepime therapy occur, the discontinuation of the drug should be considered. It is advised that patients should get in touch with their doctors if they have any inquiries or apprehensions about cefepime.

Cited Works

Food and Drug Administration. “FDA Drug Safety Communication: Cefepime and risk of seizure in patients not receiving dosage adjustments for kidney impairment.” Web 29 July, 2012 <www.fda.gov/Drugs/DrugSafety/ucm30966.htm>

Food and Drug Administration. “FDA Drug Safety Communication: Seizure risk for multiple sclerosis patients who take Ampyra (dalfampridine).” Web 29 July, 2012 <www.fda.gov/Drugs/DrugsSafety/ucm312846.htm>